There is no established standard dose for this case; it is advisable to consult a professional.
Phase 3 trial (386 high-risk people): nicotinamide 500 mg twice a day for one year reduced new non-melanoma skin cancers (basal cell and squamous cell) and actinic keratoses by ~23%. Inexpensive and safe in people with a history of these cancers.
View the study (study) →Supplement · Highest evidence: Very high · 1 finding
Information, not medical advice. Prescription drugs require a doctor.
Information, not medical advice. Scientific evidence reflects the quality of the studies.